Fetal bovine serum market seen topping $1 billion by 2030

The Business Research Company says the global fetal bovine serum market is on track to pass $1 billion by 2030, driven by rising cell culture use, biopharmaceutical R&D and research funding. North America is expected to remain the largest region, while exosome-depleted serum is projected to be the biggest product segment.

Why it matters: - Fetal bovine serum is a core input in cell culture, biopharmaceutical production and life sciences research. - The market’s projected rise to more than $1 billion by 2030 signals steady demand across drug development, vaccine work and regenerative medicine. - The market is a small slice of much larger industries, at about 1% of the life sciences market and nearly 0.1% of the pharmaceuticals market by 2030.

What happened: - The Business Research Company released a new forecast for the fetal bovine serum market covering 2026-2035. - The report puts the global market at more than $1 billion in 2030. - The market is forecast to grow at a 5% CAGR through 2030. - A free sample report is available here. - The full report is available here.

The details: - North America is projected to be the largest region in 2030, with a market value of $0.51 billion. - North America’s market is expected to grow from $0.41 billion in 2025 at a 4% CAGR. - The U.S. is projected to be the largest country market in 2030, at $0.47 billion. - The U.S. market is expected to grow from $0.38 billion in 2025 at a 5% CAGR. - The exosome-depleted product segment is expected to be the largest by 2030, accounting for 20% of the market, or $0.3 billion. - The market is segmented by product into charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell and other products. - The market is segmented by application into drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics and other applications. - The market is segmented by end user into research and academic institutes, the biotechnology and pharmaceutical industry and other end users.

Between the lines: - Demand is being pulled by more culture media use in developing countries, faster R&D for novel biopharmaceuticals and higher investment in research. - Those drivers are estimated to contribute 2.7%, 2.6% and 2.4% annual growth, respectively. - Exosome-depleted serum stands out because it supports advanced cell culture and extracellular vesicle research while reducing interference from serum-derived exosomes. - The forecast points to a market shaped less by broad consumption and more by specialized, higher-value research workflows.

What's next: - The report says the strongest growth opportunities will come from charcoal stripped, chromatographic, dialyzed, exosome-depleted, stem cell and other serum products. - Those segments are projected to add more than $0.5 billion in market value by 2030. - Over the next five years, projected growth includes $0.1 billion each for charcoal stripped, exosome depleted, stem cell and other products, $0.04 billion for dialyzed fetal bovine serum and $0.03 billion for chromatographic products. - The Business Research Company also highlighted new report features including TAM analysis, company scoring matrices, Excel forecasting dashboards and updated graphics and tables.

The bottom line: - Fetal bovine serum remains a niche but growing market, with the strongest upside tied to advanced cell culture, biomanufacturing and specialized research applications.